CIC-Mediated Modulation of MAPK Signaling Opposes Receptor Tyrosine Kinase Inhibitor Response in Kinase-Addicted Sarcoma

Scientists generated models of sarcomas bearing kinase fusions and assessed their response to molecularly targeted therapy. Immortalized, untransformed human MSCs, a putative cell-of-origin of sarcomas, were modified using CRISPR-Cas9 to harbor a RET chromosomal translocation.